Contact

It's the GeneMedi's summary page for Target/Biomarker Introduction of MPL. The page also collects GeneMedi's different modalities and formats products for MPL in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the MPL target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs . TPO-R deficient mice were severely thrombocytopenic, emphasizing the important role of CD110 and thrombopoietin in megakaryocyte and platelet formation. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated. [provided by RefSeq, Jul 2008]

Target IDGM-T16156
Target NameMPL
Gene ID4352
Gene Official NameMPL
Gene AliasC-MPL, CD110V, THCYT2, TPOR, MPL
Protein Sub-locationTransmembrane Protein
CategoryTherapeutics Target, INN Index


Pre-made MPL-specific INN-index biosimilar (antibody&conjugates)-romiplostim

Anti-MPL therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.Products Name (INN Index)INN Name Previous Name Target FormatOrder
GMP-Bios-INN-977Pre-Made Romiplostim Biosimilar, Fusion Protein targeting MPL fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting C-MPL/CD110/MPLV/THCYT2/THPOR/TPORromiplostimMPLFusion ProteinINN mab



Pre-made anti-MPL inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-MPL benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-MPL mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cat No.Antibody NameFormatClassified by tagOrder
GM-Tg-hg-T16156-AbAnti-MPL monoclonal antibodymabBiofunctional antibody, Therapeutics Target antibodymonoclonal antibody.




GENEMEDI
6th Floor, Building No.2, Kangxin Road 3377, Shanghai, China
Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
Chinese Website

Apply for
Free
Sample

Sample FOC application

×